For example, PRX177561, another CXCR4 antagonist, has been tested in GBM both in vivo and in vitro, and studies have shown that it reduces tumor growth, blocks the polarization switch of macrophages from M1 to M2 and reduces GSCs stem-like features [239]. Here, CXCR4 is linked to neoplasm.